Induction Therapy

Induction therapy is a term used to describe the first major treatment or therapy administered to a cancer patient. It does not by definition refer to any specific type of therapy in and of itself; rather, it merely refers to the initial therapeutic effort. Sometimes induction therapy goes by other names, such as 'primary therapy' or more commonly, 'first-line therapy' or 'first-line treatment.'

First-line Induction Therapy

Naturally, the hope for all patients and their doctors is that induction therapy succeed, and perhaps cure the patient of his or her cancer (this result is more common in early stage cancers, and more common in lymphoid cancers such as lymphomas and leukemias). In medicine, induction therapies amount to the best-known treatment option for each type of cancer, and typically they will be listed among standard treatment guidelines as first-line treatment options. Such standard guidelines are often not in place for very rare cancers because research has not established which treatment is the best. This does not mean then that rare cancers do not have induction therapies—every case of cancer has an induction therapy if a patient chooses to undergo therapy; the exception is only if they choose to do nothing at all about their cancer.

Induction Therapy in Lymphomas

Induction therapy for some of the more common subtypes of lymphoma are as follows:

-- Hodgkin's lymphoma: ABVD combination chemotherapy
-- Diffuse large B-cell non-Hodgkin's lymphoma: R-CHOP combination chemotherapy
-- Anaplastic large cell lymphoma: CHOP combination chemotherapy
-- Follicular lymphoma: Radiation, or single-agent Rituxan, or R-CHOP combination chemotherapy, or even the watch-and-wait approach.

Again, it doesn't matter what the choice of therapeutic intervention is, the first line of therapy is known as induction therapy. It is sometimes followed by adjuvant therapy. If induction therapy should fail, the patient would then undergo second-line therapy, which is sometimes referred to as salvage therapy.

Sources

National Cancer Institute, induction therapy

NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphoma

NCCN Clinical Practice Guidelines in Oncology: Hodgkin's Lymphoma

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap